Last reviewed · How we verify

Biohaven Therapeutics Ltd. — Portfolio Competitive Intelligence Brief

Biohaven Therapeutics Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
BHV-4157 BHV-4157 phase 3 5-HT1F receptor agonist 5-HT1F receptor Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Allergan · 1 shared drug class
  3. Amgen · 1 shared drug class
  4. Merck Sharp & Dohme LLC · 1 shared drug class
  5. NuPathe Inc. · 1 shared drug class
  6. Pfizer · 1 shared drug class
  7. Pfizer Inc. · 1 shared drug class
  8. Samsung Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biohaven Therapeutics Ltd.:

Cite this brief

Drug Landscape (2026). Biohaven Therapeutics Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biohaven-therapeutics-ltd. Accessed 2026-05-16.

Related